Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0729233 (Thoracic)
 6,478 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Thoracic duct drainage (TDD) with reinfusion of cell-free lymph was performed in 118 prospective recipients within four months before transplantation. TDD was unsuccessful in 27 patients (A); it yielded 1-19 X 10(9) lymphocytes in 25 cases (B) and 20-185 X -10(9) in 66 cases (C). The incidence of acute rejection episodes and the requirement for early post-transplant dialysis were lower in C than in A. Six patients were studied for T-lymphocyte subsets, using monoclonal antibodies from OKT series and a monomorphic and HLA-DR (BL2) raised in our laboratory. During TDD peripheral blood lymphocyte (PBL) counts decreased and the percentage of BL2 cells increased. Simultaneously, typical small PBL were replaced by large less differentiated cells slightly labelled by OKT3, some of them bearing both OKT4 and OKT8 markers. The larger the depletion, the earlier the emergence of immature T-cells. In lymph fluid, lymphocyte counts decreased later than in blood, the proportion of T8+ cells lacking Fc receptors increased with time. Changes in B patients were less than in C. These results support the hypothesis that T-cell subset modifications represent the main immunological change accounting for better allograft prognosis.
Proc Eur Dial Transplant Assoc 1983
PMID:Improvement of cadaveric renal allograft survival by thoracic duct drainage: relation with T-lymphocyte subset modifications assessed by flow-cytometry. 622 12

An elevation of blood pressure is observed in approximately 30% of dialysis patients treated with recombinant human erythropoietin (rHuEPO). Various studies have been performed in order to elucidate possible underlying mechanisms, but it is not yet well understood whether there is one major mechanism involved. In this present study, samples were obtained from male normotensive Wistar-Kyoto rats (WKY) and genetically hypertensive rats (SHR) at the age of 5 and 20 weeks. Thoracic aorta rings, with or without endothelium, isolated from WKY and SHR were used to evaluate the direct effect of rHuEPO on vascular smooth muscle by measuring the tension of vascular smooth muscle induced by various concentrations (1-100 IU/ml) of rHuEPO. Also, rHuEPO (10, 100, 1000 and 10,000 IU/kg) was intravenously administrated and the changes in mean blood pressure were recorded for 5-10 min. rHuEPO produced no significant contraction in the rat aortae in any of the preparation studies, in the presence or the absence of endothelium. The intravenous administration of rHuEPO had no immediate effect on mean blood pressure in 5- and 20-week-old WKY and SHR. These results suggest that the elevation of blood pressure observed in the clinical setting following the administration of rHuEPO is not due to a direct pressor effect on vascular smooth muscle.
Nephrol Dial Transplant 1995
PMID:Recombinant human erythropoietin has no direct or strong vasoconstrictor effects in vivo and in vitro. 756 9